Contemporary Management of HIV 2021

Gain expert insights on treatment strategies for heavily treatment–experienced patients with HIV. Topics include assessment of virologic failure, current treatment options for patients with multiclass drug resistance, and guidance on selecting the next line of therapy for patients experiencing virologic failure due to resistance.

Joseph J. Eron, Jr., MD
Program Director Princy N. Kumar, MD, FIDSA, MACP
Program Director Roger Bedimo, MD, MS, FACP Eric S. Daar, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit™ Registered Nurses: 1.0 Nursing contact hour Pharmacists: 1.0 contact hour (0.1 CEUs) Released: December 22, 2020 Expired: December 21, 2021

Scope of Problem and Assessment of Virologic Failure

Current Treatment Options for Patients With Multiclass-Resistant HIV

Patient Case 1: Expert Guidance on Selecting the Next Line of Therapy

Patient Case 2: Expert Guidance on Selecting the Next Line of Therapy

Download this expert-authored slideset to review guidelines and key data on assessing virologic failure, current management options for patients with multiclass drug resistance experiencing treatment failure, and considerations for switching ART in patients with underlying resistance.

Joseph J. Eron, Jr., MD
Program Director Princy N. Kumar, MD, FIDSA, MACP
Program Director Eric S. Daar, MD Released: March 3, 2021

Listen as expert faculty consider important clinical questions related to heavily treatment–experienced patients with HIV, including managing virologic failure and switching ART in the presence of underlying drug resistance.

Geeta Gupta, MD Released: September 1, 2021

Listen as expert faculty consider important clinical questions related to heavily treatment–experienced patients with HIV, including managing virologic failure and switching ART in the presence of underlying drug resistance.

Geeta Gupta, MD Released: September 2, 2021

Listen as expert faculty consider important clinical questions related to heavily treatment–experienced patients with HIV, including managing virologic failure and switching ART in the presence of underlying drug resistance.

Geeta Gupta, MD Released: September 7, 2021